- Home
- SGU vs SLN Comparison
SGU vs SLN Comparison
Compare SGU & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- SLN
- Stock Information
- Founded
- SGU 1995
- SLN 1994
- Country
- SGU United States
- SLN United Kingdom
- Employees
- SGU N/A
- SLN N/A
- Industry
- SGU Other Specialty Stores
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- SGU Consumer Discretionary
- SLN Health Care
- Exchange
- SGU Nasdaq
- SLN Nasdaq
- Market Cap
- SGU 390.2M
- SLN 345.3M
- IPO Year
- SGU 1995
- SLN N/A
- Fundamental
- Price
- SGU $11.95
- SLN $6.51
- Analyst Decision
- SGU
- SLN Buy
- Analyst Count
- SGU 0
- SLN 6
- Target Price
- SGU N/A
- SLN $39.67
- AVG Volume (30 Days)
- SGU 21.7K
- SLN 202.0K
- Earning Date
- SGU 12-03-2025
- SLN 11-07-2025
- Dividend Yield
- SGU 6.20%
- SLN N/A
- EPS Growth
- SGU 33.71
- SLN N/A
- EPS
- SGU 1.66
- SLN N/A
- Revenue
- SGU $1,777,057,000.00
- SLN $27,169,000.00
- Revenue This Year
- SGU N/A
- SLN N/A
- Revenue Next Year
- SGU N/A
- SLN N/A
- P/E Ratio
- SGU $7.02
- SLN N/A
- Revenue Growth
- SGU N/A
- SLN 22.28
- 52 Week Low
- SGU $10.84
- SLN $1.97
- 52 Week High
- SGU $13.75
- SLN $18.29
- Technical
- Relative Strength Index (RSI)
- SGU 56.90
- SLN 51.22
- Support Level
- SGU $11.39
- SLN $7.06
- Resistance Level
- SGU $12.17
- SLN $7.39
- Average True Range (ATR)
- SGU 0.19
- SLN 0.55
- MACD
- SGU -0.02
- SLN -0.07
- Stochastic Oscillator
- SGU 71.90
- SLN 17.05
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.